Hemophilia B Gene Therapy Market Report Infographic Image

Published : February 2026

Pages : 250

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Hemophilia B Gene Therapy Market Report 2026

Name: Hemophilia B Gene Therapy Market Report 2026
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Therapy (Adeno-Associated Viral (AAV) Vectors, Lentiviral Vectors, Retroviral Vectors), By Disease Severity (Severe Hemophilia B, Moderate Hemophilia B, Mild Hemophilia B), By Treatment Type (On-Demand, Cure, Prophylaxis), By Patient Age Group (Geriatric, Adults, Pediatric), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Purchase This Report Download Sample PDF

Item added to cart!

Hemophilia B Gene Therapy Market Overview

• Hemophilia B Gene Therapy market size has reached to $0.55 billion in 2025

• Expected to grow to $2.01 billion in 2030 at a compound annual growth rate (CAGR) of 29.8%

• Growth Driver: Increasing Preference For One-Time Curative Therapies Fueling The Growth Of The Market Due To Reduced Treatment Burden And Long-Term Disease Control

• Market Trend: Innovations In Next-Generation Gene Delivery Platforms Improve Targeting Efficiency And Treatment Performance

• North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Hemophilia B Gene Therapy Market?

Hemophilia B gene therapy refers to an advanced treatment approach in which a functional factor IX (F9) gene is delivered into a patient’s liver cells, most commonly using an adeno-associated viral (AAV) vector, enabling the body to produce its own clotting factor on a sustained basis. This therapy is designed to address the root genetic cause of the disorder and significantly reduce bleeding episodes and lifelong dependence on regular Factor IX replacement infusions through a single or long-lasting treatment.

The main types of hemophilia B gene therapy include adeno-associated viral (AAV) vectors, lentiviral vectors, and retroviral vectors. Adeno-associated viral (AAV) vectors refer to viral delivery systems engineered to carry functional copies of the factor IX gene into patient cells to restore clotting function. These therapies are used for disease severities including severe hemophilia B, moderate hemophilia B, and mild hemophilia B. They are available in treatment types such as on-demand, cure, and prophylaxis, and administered across patient age groups including geriatric, adults, and pediatric populations. They are distributed through hospital pharmacies and specialty pharmacies.

Hemophilia B Gene Therapy Market Report bar graph

What Is The Hemophilia B Gene Therapy Market Size and Share 2026?

The hemophilia b gene therapy market size has grown exponentially in recent years. It will grow from $0.55 billion in 2025 to $0.71 billion in 2026 at a compound annual growth rate (CAGR) of 29.6%. The growth in the historic period can be attributed to improvements in gene delivery technologies, increased understanding of hemophilia b genetics, expansion of clinical research programs, rising burden of lifelong replacement therapy, availability of specialized treatment centers.

What Is The Hemophilia B Gene Therapy Market Growth Forecast?

The hemophilia b gene therapy market size is expected to see exponential growth in the next few years. It will grow to $2.01 billion in 2030 at a compound annual growth rate (CAGR) of 29.8%. The growth in the forecast period can be attributed to increasing approvals of gene therapies, rising investments in rare disease treatments, growing demand for durable therapeutic outcomes, expansion of advanced manufacturing capabilities, increasing patient access programs. Major trends in the forecast period include increasing progress in one-time curative therapies, rising focus on long-term factor ix expression, growing optimization of aav vector design, expansion of personalized gene therapy approaches, enhanced regulatory alignment for advanced therapies.

Book your 30 minutes free consultation with our research experts

Global Hemophilia B Gene Therapy Market Segmentation

1) By Therapy: Adeno-Associated Viral (AAV) Vectors; Lentiviral Vectors; Retroviral Vectors

2) By Disease Severity: Severe Hemophilia B; Moderate Hemophilia B; Mild Hemophilia B

3) By Treatment Type: On-Demand; Cure; Prophylaxis

4) By Patient Age Group: Geriatric; Adults; Pediatric

5) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies

Subsegments:

1) By Adeno-Associated Viral Vectors: Single-Stranded Adeno-Associated Viral Vectors; Self-Complementary Adeno-Associated Viral Vectors; Tissue Specific Promoter Adeno-Associated Viral Vectors; Capsid Modified Adeno-Associated Viral Vectors

2) By Lentiviral Vectors: Integrating Lentiviral Vectors; Non-Integrating Lentiviral Vectors; Self-Inactivating Lentiviral Vectors; Pseudotyped Lentiviral Vectors

3) By Retroviral Vectors: Gamma Retroviral Vectors; Alpha Retroviral Vectors; Moloney Murine Leukemia Virus Retroviral Vectors; Spumaretroviral Vectors

What Are The Drivers Of The Hemophilia B Gene Therapy Market?

The rising number of gene therapy clinical trials is expected to propel the growth of the hemophilia B gene therapy market going forward. Gene therapy clinical trials are research studies designed to evaluate the safety, efficacy, and long-term therapeutic potential of gene-based treatments in human participants. The increase in gene therapy clinical trials is driven by growing investment from biopharmaceutical companies, advancements in viral vector technology, supportive regulatory frameworks, and the need to address rare genetic disorders with high unmet medical need, including hemophilia B. Hemophilia B gene therapy is benefiting from this expanding gene therapy clinical trial landscape by leveraging established clinical development pathways, regulatory experience, and manufacturing capabilities associated with in vivo gene delivery approaches. For instance, in January 2026, according to Bioindustry Association (BIA) a UK-based national trade association, UK recorded 193 ongoing advanced therapy clinical trials, broadly similar to 2024, with over half in early stages, around 80% commercially sponsored, and more than 80% focused on gene therapies, evenly split between ex vivo and in vivo approaches. Therefore, the rising cell and gene therapy clinical trials is driving the growth of the hemophilia B gene therapy industry.

The rising adoption of personalized medicine is expected to propel the growth of the hemophilia B gene therapy market going forward. Personalized medicine refers to a medical approach that tailors disease prevention, diagnosis, and treatment based on an individual’s genetic, molecular, or clinical characteristics to improve therapeutic outcomes and reduce adverse effects. The increasing adoption of personalized medicine is driven by advancements in genomics, improved biomarker identification, and growing regulatory support for targeted therapies that move away from one-size-fits-all treatment models. Hemophilia B gene therapy aligns closely with the principles of personalized medicine by targeting the underlying genetic cause of the disease and enabling long-term therapeutic benefit through individualized gene-based interventions. These therapies rely on patient-specific genetic and clinical profiling to determine eligibility, optimize dosing strategies, and monitor treatment durability and safety. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the US Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023. Therefore, the rising adoption of personalized medicine is driving the growth of the hemophilia B gene therapy industry.

Key Players In The Global Hemophilia B Gene Therapy Market

Major companies operating in the hemophilia b gene therapy market are REGENXBIO Inc., Pfizer Inc., Bayer Aktiengesellschaft (Bayer AG), Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, CSL Behring LLC, Lonza Group AG, Alnylam Pharmaceuticals Inc., GenScript ProBio LLC, Ultragenyx Pharmaceutical Inc., Takara Bio Inc., Sangamo Therapeutics Inc., Precision BioSciences Inc., Synthego Corporation, MaxCyte Inc., uniQure N.V., Freeline Therapeutics Ltd., Be Biopharma Inc., Asklepios BioPharmaceutical Inc., Cellectis S.A.

Global Hemophilia B Gene Therapy Market Trends and Insights

Major companies operating in the hemophilia B gene therapy market are increasingly focusing on innovations in next-generation gene delivery platforms, particularly optimized adeno-associated virus (AAV)–based vector systems, to enhance therapeutic efficacy and safety. Optimized AAV-based vector systems serve as advanced viral delivery platforms that enable efficient and controlled transfer of functional clotting factor IX genes into target hepatocytes, supporting long-term endogenous factor production. For instance, in May 2023, CSL Behring GmbH, a Germany-based biotechnology company, received European Commission approval for HEMGENIX, the first gene therapy approved for the treatment of hemophilia B. HEMGENIX is indicated for adult patients with severe or moderate hemophilia B without a history of factor IX inhibitors and is designed to reduce or eliminate the need for routine factor IX prophylaxis. According to results from the pivotal HOPE-B clinical study, a significant proportion of treated patients no longer required regular factor IX infusions, demonstrating sustained therapeutic benefit and highlighting the potential of next-generation AAV-based gene therapies in long-term disease management.

Need data on a specific region in this market?

Request Regional Data

Regional Insights

North America was the largest region in the hemophilia b gene therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Hemophilia B Gene Therapy Market?

The hemophilia B gene therapy market includes revenues earned by entities through gene therapy research and development, vector design and optimization services, clinical trial management services, patient screening and eligibility assessment services, genetic testing and sequencing services, and regulatory consulting and approval services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hemophilia B Gene Therapy Market Report 2026?

The hemophilia b gene therapy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hemophilia b gene therapy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

Hemophilia B Gene Therapy Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2026	$0.71 billion
Revenue Forecast In 2035	$2.01 billion
Growth Rate	CAGR of 29.6% from 2026 to 2035
Base Year For Estimation	2025
Actual Estimates/Historical Data	2020-2025
Forecast Period	2026 - 2030 - 2035
Market Representation	Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered	Therapy, Disease Severity, Treatment Type, Patient Age Group, Distribution Channel
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled	REGENXBIO Inc., Pfizer Inc., Bayer Aktiengesellschaft (Bayer AG), Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, CSL Behring LLC, Lonza Group AG, Alnylam Pharmaceuticals Inc., GenScript ProBio LLC, Ultragenyx Pharmaceutical Inc., Takara Bio Inc., Sangamo Therapeutics Inc., Precision BioSciences Inc., Synthego Corporation, MaxCyte Inc., uniQure N.V., Freeline Therapeutics Ltd., Be Biopharma Inc., Asklepios BioPharmaceutical Inc., Cellectis S.A.
Customization Scope	Request for Customization
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Hemophilia B Gene Therapy Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Hemophilia B Gene Therapy Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Hemophilia B Gene Therapy Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Hemophilia B Gene Therapy Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Digitalization, Cloud, Big Data & Cybersecurity

4.1.3 Artificial Intelligence & Autonomous Intelligence

4.1.4 Industry 4.0 & Intelligent Manufacturing

4.1.5 Sustainability, Climate Tech & Circular Economy

4.2. Major Trends

4.2.1 Increasing Progress In One-Time Curative Therapies

4.2.2 Rising Focus On Long-Term Factor Ix Expression

4.2.3 Growing Optimization Of Aav Vector Design

4.2.4 Expansion Of Personalized Gene Therapy Approaches

4.2.5 Enhanced Regulatory Alignment For Advanced Therapies

5. Hemophilia B Gene Therapy Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Specialty Clinics

5.3 Gene Therapy Developers

5.4 Biopharmaceutical Companies

5.5 Research Institutes

6. Hemophilia B Gene Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Hemophilia B Gene Therapy Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Hemophilia B Gene Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Hemophilia B Gene Therapy Market Size, Comparisons And Growth Rate Analysis

7.3. Global Hemophilia B Gene Therapy Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Hemophilia B Gene Therapy Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Hemophilia B Gene Therapy Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Hemophilia B Gene Therapy Market Segmentation

9.1. Global Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Adeno-Associated Viral (AAV) Vectors, Lentiviral Vectors, Retroviral Vectors

9.2. Global Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Severe Hemophilia B, Moderate Hemophilia B, Mild Hemophilia B

9.3. Global Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

On-Demand, Cure, Prophylaxis

9.4. Global Hemophilia B Gene Therapy Market, Segmentation By Patient Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Geriatric, Adults, Pediatric

9.5. Global Hemophilia B Gene Therapy Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospital Pharmacies, Specialty Pharmacies

9.6. Global Hemophilia B Gene Therapy Market, Sub-Segmentation Of Adeno-Associated Viral Vectors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Single-Stranded Adeno-Associated Viral Vectors, Self-Complementary Adeno-Associated Viral Vectors, Tissue Specific Promoter Adeno-Associated Viral Vectors, Capsid Modified Adeno-Associated Viral Vectors

9.7. Global Hemophilia B Gene Therapy Market, Sub-Segmentation Of Lentiviral Vectors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Integrating Lentiviral Vectors, Non-Integrating Lentiviral Vectors, Self-Inactivating Lentiviral Vectors, Pseudotyped Lentiviral Vectors

9.8. Global Hemophilia B Gene Therapy Market, Sub-Segmentation Of Retroviral Vectors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Gamma Retroviral Vectors, Alpha Retroviral Vectors, Moloney Murine Leukemia Virus Retroviral Vectors, Spumaretroviral Vectors

10. Hemophilia B Gene Therapy Market Regional And Country Analysis

10.1. Global Hemophilia B Gene Therapy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Hemophilia B Gene Therapy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Hemophilia B Gene Therapy Market

11.1. Asia-Pacific Hemophilia B Gene Therapy Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Hemophilia B Gene Therapy Market, Segmentation By Therapy, Segmentation By Disease Severity, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Hemophilia B Gene Therapy Market

12.1. China Hemophilia B Gene Therapy Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Hemophilia B Gene Therapy Market, Segmentation By Therapy, Segmentation By Disease Severity, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Hemophilia B Gene Therapy Market

13.1. India Hemophilia B Gene Therapy Market, Segmentation By Therapy, Segmentation By Disease Severity, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Hemophilia B Gene Therapy Market

14.1. Japan Hemophilia B Gene Therapy Market Overview

14.2. Japan Hemophilia B Gene Therapy Market, Segmentation By Therapy, Segmentation By Disease Severity, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Hemophilia B Gene Therapy Market

15.1. Australia Hemophilia B Gene Therapy Market, Segmentation By Therapy, Segmentation By Disease Severity, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Hemophilia B Gene Therapy Market

16.1. Indonesia Hemophilia B Gene Therapy Market, Segmentation By Therapy, Segmentation By Disease Severity, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Hemophilia B Gene Therapy Market

17.1. South Korea Hemophilia B Gene Therapy Market Overview

17.2. South Korea Hemophilia B Gene Therapy Market, Segmentation By Therapy, Segmentation By Disease Severity, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Hemophilia B Gene Therapy Market

18.1. Taiwan Hemophilia B Gene Therapy Market Overview

18.2. Taiwan Hemophilia B Gene Therapy Market, Segmentation By Therapy, Segmentation By Disease Severity, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Hemophilia B Gene Therapy Market

19.1. South East Asia Hemophilia B Gene Therapy Market Overview

19.2. South East Asia Hemophilia B Gene Therapy Market, Segmentation By Therapy, Segmentation By Disease Severity, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Hemophilia B Gene Therapy Market

20.1. Western Europe Hemophilia B Gene Therapy Market Overview

20.2. Western Europe Hemophilia B Gene Therapy Market, Segmentation By Therapy, Segmentation By Disease Severity, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Hemophilia B Gene Therapy Market

21.1. UK Hemophilia B Gene Therapy Market, Segmentation By Therapy, Segmentation By Disease Severity, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Hemophilia B Gene Therapy Market

22.1. Germany Hemophilia B Gene Therapy Market, Segmentation By Therapy, Segmentation By Disease Severity, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Hemophilia B Gene Therapy Market

23.1. France Hemophilia B Gene Therapy Market, Segmentation By Therapy, Segmentation By Disease Severity, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Hemophilia B Gene Therapy Market

24.1. Italy Hemophilia B Gene Therapy Market, Segmentation By Therapy, Segmentation By Disease Severity, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Hemophilia B Gene Therapy Market

25.1. Spain Hemophilia B Gene Therapy Market, Segmentation By Therapy, Segmentation By Disease Severity, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Hemophilia B Gene Therapy Market

26.1. Eastern Europe Hemophilia B Gene Therapy Market Overview

26.2. Eastern Europe Hemophilia B Gene Therapy Market, Segmentation By Therapy, Segmentation By Disease Severity, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Hemophilia B Gene Therapy Market

27.1. Russia Hemophilia B Gene Therapy Market, Segmentation By Therapy, Segmentation By Disease Severity, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Hemophilia B Gene Therapy Market

28.1. North America Hemophilia B Gene Therapy Market Overview

28.2. North America Hemophilia B Gene Therapy Market, Segmentation By Therapy, Segmentation By Disease Severity, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Hemophilia B Gene Therapy Market

29.1. USA Hemophilia B Gene Therapy Market Overview

29.2. USA Hemophilia B Gene Therapy Market, Segmentation By Therapy, Segmentation By Disease Severity, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Hemophilia B Gene Therapy Market

30.1. Canada Hemophilia B Gene Therapy Market Overview

30.2. Canada Hemophilia B Gene Therapy Market, Segmentation By Therapy, Segmentation By Disease Severity, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Hemophilia B Gene Therapy Market

31.1. South America Hemophilia B Gene Therapy Market Overview

31.2. South America Hemophilia B Gene Therapy Market, Segmentation By Therapy, Segmentation By Disease Severity, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Hemophilia B Gene Therapy Market

32.1. Brazil Hemophilia B Gene Therapy Market, Segmentation By Therapy, Segmentation By Disease Severity, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Hemophilia B Gene Therapy Market

33.1. Middle East Hemophilia B Gene Therapy Market Overview

33.2. Middle East Hemophilia B Gene Therapy Market, Segmentation By Therapy, Segmentation By Disease Severity, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Hemophilia B Gene Therapy Market

34.1. Africa Hemophilia B Gene Therapy Market Overview

34.2. Africa Hemophilia B Gene Therapy Market, Segmentation By Therapy, Segmentation By Disease Severity, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Hemophilia B Gene Therapy Market Regulatory and Investment Landscape

36. Hemophilia B Gene Therapy Market Competitive Landscape And Company Profiles

36.1. Hemophilia B Gene Therapy Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Hemophilia B Gene Therapy Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Hemophilia B Gene Therapy Market Company Profiles

36.3.1. REGENXBIO Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.3. Bayer Aktiengesellschaft (Bayer AG) Overview, Products and Services, Strategy and Financial Analysis

36.3.4. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.5. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

37. Hemophilia B Gene Therapy Market Other Major And Innovative Companies

Merck KGaA, CSL Behring LLC, Lonza Group AG, Alnylam Pharmaceuticals Inc., GenScript ProBio LLC, Ultragenyx Pharmaceutical Inc., Takara Bio Inc., Sangamo Therapeutics Inc., Precision BioSciences Inc., Synthego Corporation, MaxCyte Inc., uniQure N.V., Freeline Therapeutics Ltd., Be Biopharma Inc., Asklepios BioPharmaceutical Inc.

38. Global Hemophilia B Gene Therapy Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Hemophilia B Gene Therapy Market

41. Hemophilia B Gene Therapy Market High Potential Countries, Segments and Strategies

41.1 Hemophilia B Gene Therapy Market In 2030 - Countries Offering Most New Opportunities

41.2 Hemophilia B Gene Therapy Market In 2030 - Segments Offering Most New Opportunities

41.3 Hemophilia B Gene Therapy Market In 2030 - Growth Strategies

41.3.1 Market Trend Based Strategies

41.3.2 Competitor Strategies

42. Appendix

42.1. Abbreviations

42.2. Currencies

42.3. Historic And Forecast Inflation Rates

42.4. Research Inquiries

42.5. The Business Research Company

42.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Hemophilia B Gene Therapy Market, Overview Of Key Products - Product Examples

Table 2: Global Hemophilia B Gene Therapy Market Attractiveness, Factor-Wise Evaluation

Table 3: Global Hemophilia B Gene Therapy Market, Supply Chain Analysis

Table 4: Global Hemophilia B Gene Therapy Market, Major Raw Material Providers

Table 5: Global Hemophilia B Gene Therapy Market, Major Resource Providers

Table 6: Global Hemophilia B Gene Therapy Market, Major Manufacturers (Suppliers)

Table 7: Global Hemophilia B Gene Therapy Market, Major Distributors And Channel Partners

Table 8: Global Hemophilia B Gene Therapy Market, Key Technologies & Future Trends

Table 9: Global Hemophilia B Gene Therapy Market, Major Trends

Table 10: Global Hemophilia B Gene Therapy Market, Major End Users

Table 11: Global Hemophilia B Gene Therapy Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Table 12: Global Hemophilia B Gene Therapy Historic Market Growth, 2020-2025, $ Billion

Table 13: Global Hemophilia B Gene Therapy Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Table 14: Global Hemophilia B Gene Therapy Market - TAM, US$ Billion, 2025

Table 15: Global Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 16: Global Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 17: Global Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 18: Global Hemophilia B Gene Therapy Market, Segmentation By Patient Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 19: Global Hemophilia B Gene Therapy Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 20: Global Hemophilia B Gene Therapy Market, Sub-Segmentation Of Adeno-Associated Viral Vectors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 21: Global Hemophilia B Gene Therapy Market, Sub-Segmentation Of Lentiviral Vectors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 22: Global Hemophilia B Gene Therapy Market, Sub-Segmentation Of Retroviral Vectors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 23: Global Hemophilia B Gene Therapy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 24: Global Hemophilia B Gene Therapy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 25: Asia-Pacific, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 26: Asia-Pacific, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 27: Asia-Pacific, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 28: China, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 29: China, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 30: China, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 31: India, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 32: India, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 33: India, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 34: Japan, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 35: Japan, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 36: Japan, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 37: Australia, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 38: Australia, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 39: Australia, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 40: Indonesia, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 41: Indonesia, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 42: Indonesia, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 43: South Korea, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 44: South Korea, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 45: South Korea, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 46: Taiwan, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 47: Taiwan, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 48: Taiwan, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 49: South East Asia, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 50: South East Asia, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 51: South East Asia, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 52: Western Europe, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 53: Western Europe, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 54: Western Europe, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 55: UK, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 56: UK, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 57: UK, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 58: Germany, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 59: Germany, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 60: Germany, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 61: France, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 62: France, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 63: France, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 64: Italy, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 65: Italy, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 66: Italy, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 67: Spain, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 68: Spain, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 69: Spain, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 70: Eastern Europe, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 71: Eastern Europe, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 72: Eastern Europe, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 73: Russia, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 74: Russia, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 75: Russia, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 76: North America, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 77: North America, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 78: North America, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 79: USA, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 80: USA, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 81: USA, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 82: Canada, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 83: Canada, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 84: Canada, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 85: South America, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 86: South America, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 87: South America, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 88: Brazil, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 89: Brazil, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 90: Brazil, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 91: Middle East, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 92: Middle East, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 93: Middle East, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 94: Africa, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 95: Africa, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 96: Africa, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 97: Global Hemophilia B Gene Therapy Key Competitor Estimated Market Shares, 2024, Percentage (%)

Table 98: Global Hemophilia B Gene Therapy Market - Company Scoring Matrix

Table 99: Upcoming Startups

Table 100: REGENXBIO Inc. Financial Performance

Table 101: Pfizer Inc. Financial Performance

Table 102: Bayer Aktiengesellschaft (Bayer AG) Financial Performance

Table 103: Thermo Fisher Scientific Inc. Financial Performance

Table 104: Takeda Pharmaceutical Company Limited Financial Performance

Table 105: Global Hemophilia B Gene Therapy Market, Competitive Benchmarking (In USD Billions)

Table 106: Global Hemophilia B Gene Therapy Market, Competitive Dashboard

Table 107: Global Hemophilia B Gene Therapy Market Size Gain ($ Billion), 2025 – 2030 By Country

Table 108: Global, Hemophilia B Gene Therapy Market Size Gain ($ Billion), Segmentation By Therapy, 2025 – 2030

Table 109: Global, Hemophilia B Gene Therapy Market Size Gain ($ Billion), Segmentation By Disease Severity, 2025 – 2030

Table 110: Global, Hemophilia B Gene Therapy Market Size Gain ($ Billion), Segmentation By Treatment Type, 2025 – 2030

List Of Figures

Figure 1: Global Hemophilia B Gene Therapy Market, Overview Of Key Products - Product Examples

Figure 2: Global Hemophilia B Gene Therapy Market Attractiveness, Factor-Wise Evaluation

Figure 3: Global Hemophilia B Gene Therapy Market, Supply Chain Analysis

Figure 4: Global Hemophilia B Gene Therapy Market, Major Raw Material Providers

Figure 5: Global Hemophilia B Gene Therapy Market, Major Resource Providers

Figure 6: Global Hemophilia B Gene Therapy Market, Major Manufacturers (Suppliers)

Figure 7: Global Hemophilia B Gene Therapy Market, Major Distributors And Channel Partners

Figure 8: Global Hemophilia B Gene Therapy Market, Key Technologies & Future Trends

Figure 9: Global Hemophilia B Gene Therapy Market, Major Trends

Figure 10: Global Hemophilia B Gene Therapy Market, Major End Users

Figure 11: Global Hemophilia B Gene Therapy Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Figure 12: Global Hemophilia B Gene Therapy Historic Market Growth, 2020-2025, $ Billion

Figure 13: Global Hemophilia B Gene Therapy Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Figure 14: Global Hemophilia B Gene Therapy Market - TAM, US$ Billion, 2025

Figure 15: Global Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 16: Global Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 17: Global Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 18: Global Hemophilia B Gene Therapy Market, Segmentation By Patient Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 19: Global Hemophilia B Gene Therapy Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 20: Global Hemophilia B Gene Therapy Market, Sub-Segmentation Of Adeno-Associated Viral Vectors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 21: Global Hemophilia B Gene Therapy Market, Sub-Segmentation Of Lentiviral Vectors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 22: Global Hemophilia B Gene Therapy Market, Sub-Segmentation Of Retroviral Vectors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 23: Global Hemophilia B Gene Therapy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 24: Global Hemophilia B Gene Therapy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 25: Asia-Pacific, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 26: Asia-Pacific, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 27: Asia-Pacific, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 28: China, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 29: China, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 30: China, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 31: India, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 32: India, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 33: India, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 34: Japan, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 35: Japan, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 36: Japan, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 37: Australia, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 38: Australia, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 39: Australia, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 40: Indonesia, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 41: Indonesia, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 42: Indonesia, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 43: South Korea, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 44: South Korea, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 45: South Korea, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 46: Taiwan, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 47: Taiwan, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 48: Taiwan, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 49: South East Asia, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 50: South East Asia, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 51: South East Asia, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 52: Western Europe, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 53: Western Europe, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 54: Western Europe, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 55: UK, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 56: UK, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 57: UK, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 58: Germany, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 59: Germany, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 60: Germany, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 61: France, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 62: France, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 63: France, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 64: Italy, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 65: Italy, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 66: Italy, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 67: Spain, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 68: Spain, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 69: Spain, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 70: Eastern Europe, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 71: Eastern Europe, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 72: Eastern Europe, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 73: Russia, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 74: Russia, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 75: Russia, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 76: North America, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 77: North America, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 78: North America, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 79: USA, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 80: USA, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 81: USA, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 82: Canada, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 83: Canada, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 84: Canada, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 85: South America, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 86: South America, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 87: South America, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 88: Brazil, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 89: Brazil, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 90: Brazil, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 91: Middle East, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 92: Middle East, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 93: Middle East, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 94: Africa, Hemophilia B Gene Therapy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 95: Africa, Hemophilia B Gene Therapy Market, Segmentation By Disease Severity, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 96: Africa, Hemophilia B Gene Therapy Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 97: Global Hemophilia B Gene Therapy Key Competitor Estimated Market Shares, 2024, Percentage (%)

Figure 98: Global Hemophilia B Gene Therapy Market - Company Scoring Matrix

Figure 99: Upcoming Startups

Figure 100: REGENXBIO Inc. Financial Performance

Figure 101: Pfizer Inc. Financial Performance

Figure 102: Bayer Aktiengesellschaft (Bayer AG) Financial Performance

Figure 103: Thermo Fisher Scientific Inc. Financial Performance

Figure 104: Takeda Pharmaceutical Company Limited Financial Performance

Figure 105: Global Hemophilia B Gene Therapy Market, Competitive Benchmarking (In USD Billions)

Figure 106: Global Hemophilia B Gene Therapy Market, Competitive Dashboard

Figure 107: Global Hemophilia B Gene Therapy Market Size Gain ($ Billion), 2025 – 2030 By Country

Figure 108: Global, Hemophilia B Gene Therapy Market Size Gain ($ Billion), Segmentation By Therapy, 2025 – 2030

Figure 109: Global, Hemophilia B Gene Therapy Market Size Gain ($ Billion), Segmentation By Disease Severity, 2025 – 2030

Figure 110: Global, Hemophilia B Gene Therapy Market Size Gain ($ Billion), Segmentation By Treatment Type, 2025 – 2030

Advanced Therapy Medicinal Products Industry Poised for Rapid Expansion, Projected to Hit $104.43 Billion by 2029

Global Insights: Androgen Deprivation Therapy Market Expected to Surpass $10.49 Billion by 2029

2025 Anti-CD20 Monoclonal Antibodies Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Future Projections: Anti-D Immunoglobulin Market to Reach $3.34 Billion by 2029 at 6.6% CAGR

Anti-Inflammatory Biologics Market Revenue Outlook: Strategic Insights and Forecast to 2029

CAGR of 10.8% Projected for Anti-Tumor Drugs Market From 2025 to 2029

Future Demand and Leading Companies Shaping the Asthma Disease Market to 2029

Comprehensive Forecast: Asthma Therapeutics Market Share, Growth, and Opportunities Through 2029

Hepatitis Therapeutics Market Report 2026 - Global Outlook – By Disease Type (Hepatitis A, Hepatitis B, Hepatitis C, Other Disease Types), By Drug Class (Oral Antivirals, Immune Modulators), By Distribution Channel (Hosp...

Acquired Hemophilia Treatment Market Report 2026 - Global Outlook – By Treatment Approach (Bleeding Control Therapy (On-Demand Treatment), Inhibitor Eradication Therapy (Immunosuppressive Treatment)), By Route of Adminis...

Hemophilia Market Report 2026 - Global Outlook – By Type (Hemophilia A, Hemophilia B, Hemophilia C, Other Types), By Treatment (Replacement Therapy, Hemostatic Agents, Desmopressin, Gene Therapy, Other Treatments), By En...

Preventive Vaccines Market Report 2026 - Global Outlook – By Type (Live Or Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit Vaccines, Conjugate Vaccines, DNA Vaccines, Recombinant Vector Vaccines), By ...

Cell And Gene Therapy Supply Chain/Logistics Market Report 2026 - Global Outlook – By Type Of Software Solution (Cell Orchestration Platform, Enterprise Manufacturing System, Inventory Management System, Laboratory Infor...

Gene Therapy Market Report 2026 - Global Outlook – By Gene Therapy Type (Germline Therapy, Somatic Cell Therapy), By Vector (Viral Vector, Non-Viral Vector), By Application (Oncology, Orphan Disease, Knee Osteoarthritis,...

Cell And Gene Therapy Clinical Trial Services Market Report 2026 - Global Outlook – By Service (Clinical Trial Design And Planning, Supply And Logistic Services, Regulatory Affairs And Compliance, Data Management And Bio...

Frequently Asked Questions

How big is the Hemophilia B Gene Therapy Market?

The Hemophilia B Gene Therapy market was valued at $0.55 billion in 2025, increased to $0.71 billion in 2026, and is projected to reach $2.01 billion by 2030.

What is the Hemophilia B Gene Therapy market growth?

The global Hemophilia B Gene Therapy market is expected to grow at a CAGR of 29.8% from 2026 to 2035 to reach $2.01 billion by 2035.

Who are the key players in Hemophilia B Gene Therapy market?

Some Key Players in the Hemophilia B Gene Therapy market Include, REGENXBIO Inc., Pfizer Inc., Bayer Aktiengesellschaft (Bayer AG), Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, CSL Behring LLC, Lonza Group AG, Alnylam Pharmaceuticals Inc., GenScript ProBio LLC, Ultragenyx Pharmaceutical Inc., Takara Bio Inc., Sangamo Therapeutics Inc., Precision BioSciences Inc., Synthego Corporation, MaxCyte Inc., uniQure N.V., Freeline Therapeutics Ltd., Be Biopharma Inc., Asklepios BioPharmaceutical Inc., Cellectis S.A. .

What is the anticipated growth trend for the Hemophilia B Gene Therapy market?

Major trend in this market includes: Innovations In Next-Generation Gene Delivery Platforms Improve Targeting Efficiency And Treatment Performance. For further insights on this market. request a sample here

Which region has the most growth potential in the Hemophilia B Gene Therapy market?

North America was the largest region in the hemophilia b gene therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hemophilia b gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.